Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 117 entries
View as:

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT07020988 Org: User:
Start: 07/31/25 End: 01/29/26 Due: 01/29/27

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06011733 Org: User:
Start: 10/31/23 End: 02/05/25 Due: 02/05/26

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Phase: N/A Priority: Normal
NCT ID: NCT04875975 Org: User:
Start: 09/27/21 End: 04/26/24 Due: 04/26/25

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06506916 Org: User:
Start: 07/29/24 End: 03/14/28 Due: 03/14/29

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Phase: N/A Priority: Normal
NCT ID: NCT04163016 Org: User:
Start: 06/19/20 End: 05/23/23 Due: 05/23/24

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04828343 Org: User:
Start: 04/22/21 End: 04/11/22 Due: 04/11/23

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Phase: N/A Priority: Normal
NCT ID: NCT05014724 Org: User:
Start: - End: - Due: -

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

Phase: N/A Priority: Normal
NCT ID: NCT04335578 Org: User:
Start: 10/21/19 End: 05/04/22 Due: 05/04/23

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03412747 Org: User:
Start: 01/26/18 End: 02/26/20 Due: 02/26/21

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03410992 Org: User:
Start: 02/05/18 End: 01/07/20 Due: 01/07/21

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT04224688 Org: User:
Start: 06/03/20 End: 05/05/22 Due: 05/05/23

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

Phase: N/A Priority: Normal
NCT ID: NCT04782388 Org: User:
Start: 03/04/21 End: 04/26/21 Due: 04/26/22

Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT03559686 Org: User:
Start: - End: - Due: -

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04393298 Org: User:
Start: 07/09/20 End: 04/11/24 Due: 04/11/25

A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

Phase: N/A Priority: Normal
NCT ID: NCT03325439 Org: User:
Start: 05/07/19 End: 05/29/21 Due: 05/29/22

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT06716879 Org: User:
Start: 12/06/24 End: 04/04/25 Due: 04/04/26

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Phase: N/A Priority: Normal
NCT ID: NCT04658199 Org: User:
Start: 11/16/20 End: 03/30/27 Due: 03/30/28

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04124965 Org: User:
Start: 10/29/19 End: 09/01/21 Due: 09/01/22

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03083665 Org: User:
Start: 08/22/17 End: 06/30/22 Due: 06/30/23

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT04666610 Org: User:
Start: 07/29/21 End: 02/25/27 Due: 02/25/28

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Phase: N/A Priority: Normal
NCT ID: NCT03250377 Org: User:
Start: 08/05/17 End: 12/24/24 Due: 12/24/25

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT04200456 Org: User:
Start: 01/31/20 End: 04/27/22 Due: 04/27/23

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Phase: N/A Priority: Normal
NCT ID: NCT03766685 Org: User:
Start: 12/20/18 End: 09/08/20 Due: 09/08/21

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Phase: N/A Priority: Normal
NCT ID: NCT03248531 Org: User:
Start: 09/22/17 End: 02/21/19 Due: 02/21/20

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04650854 Org: User:
Start: 02/03/21 End: 01/25/24 Due: 01/25/25